Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D N Gerding

Showing results (181-190 of 193) with videos related to

Pageof 20
Sort By:
Antimicrobial Agents and Chemotherapy|December 11, 1992
Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapyJ A Korvick, C S Bryan, B Farber, et al.
Clinical Therapeutics|January 1, 1987
Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoximeC E Hughes, C C Johnson, D M Bamberger, et al.
The Journal of Infectious Diseases|November 1, 1991
gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and TennesseeC E Fasching, F C Tenover, T G Slama, et al.
Anaerobe|May 11, 2020
Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016D R Snydman, L A McDermott, S G Jenkins, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2019
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016C M Thorpe, L A McDermott, M K Tran, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to FidaxomicinD R Snydman, L A McDermott, N V Jacobus, et al.
The New England Journal of Medicine|November 26, 1999
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitalsS Johnson, M H Samore, K A Farrow, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2015
Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infectionD N Gerding, D W Hecht, T Louie, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2023
A US-based national surveillance study for the susceptibility and epidemiology of <i>Clostridioides difficile</i> isolates with special reference to ridinilazole: 2020-2021D R Snydman, L A McDermott, C M Thorpe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 1997
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitalsD M Shlaes, D N Gerding, J F John, et al.
Pageof 20

Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
Antimicrobial Agents and Chemotherapy|December 11, 1992
Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapyJ A Korvick, C S Bryan, B Farber, et al.
Clinical Therapeutics|January 1, 1987
Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoximeC E Hughes, C C Johnson, D M Bamberger, et al.
The Journal of Infectious Diseases|November 1, 1991
gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and TennesseeC E Fasching, F C Tenover, T G Slama, et al.
Anaerobe|May 11, 2020
Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016D R Snydman, L A McDermott, S G Jenkins, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2019
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016C M Thorpe, L A McDermott, M K Tran, et al.
Antimicrobial Agents and Chemotherapy|August 5, 2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to FidaxomicinD R Snydman, L A McDermott, N V Jacobus, et al.
The New England Journal of Medicine|November 26, 1999
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitalsS Johnson, M H Samore, K A Farrow, et al.
The Journal of Antimicrobial Chemotherapy|October 5, 2015
Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infectionD N Gerding, D W Hecht, T Louie, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2023
A US-based national surveillance study for the susceptibility and epidemiology of <i>Clostridioides difficile</i> isolates with special reference to ridinilazole: 2020-2021D R Snydman, L A McDermott, C M Thorpe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 1997
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitalsD M Shlaes, D N Gerding, J F John, et al.
Pageof 20